Two phase 3 studies on ultra-long-acting insulin degludec published in The Lancet
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
List view / Grid view
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
23 April 2012 | By Amgen
Amgen has announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away...
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
20 April 2012 | By Abbott
Abbott has received U.S. FDA clearance to use its iFS Advanced Femtosecond Laser...
19 April 2012 | By Sanofi
Fox Foundation to sponsor a clinical trial to study Sanofi compound...
18 April 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces plans to launch an exciting new phase of the initiative...
18 April 2012 | By Teva Pharmaceutical Industries Ltd
TEVA announced new data from the Company's expanding CNS portfolio...
18 April 2012 | By Roche
Roche released the following statement based on preliminary estimates...
18 April 2012 | By Boehringer Ingelheim
A new analysis of the 18,113 patient...
Bringing new insect silk products to the global market is the focus of a partnership announced today by Australian research agency CSIRO and global life science industry supplier Lonza.
18 April 2012 | By Merck
Merck said a state court jury in New Jersey found in its favor in the Sessner v. Merck case...
18 April 2012 | By Gilead Sciences
Presentations include first results for lead hepatitis C candidate GS-7977 in treatment-naïve genotype 1 patients...
17 April 2012 | By Abbott
Detection of gene abnormalities may help men determine the best approach to treatment...